一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Association of c-Myc and Immune Cell Infiltration in Small Cell Lung Carcinoma.
Association of c-Myc and Immune Cell Infiltration in Small Cell Lung Carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
c-Myc 在 SCLC 中的表达与免疫浸润相关,并可能通过 WNT/β-catenin 信号通路调控 SCLC 细胞上免疫相关配体的表达。
小细胞肺癌(SCLC)是一种高度侵袭性、快速增殖的恶性肿瘤,很大程度上对应于免疫冷肿瘤类型。关键癌基因c-Myc在调控SCLC复杂免疫微环境中的作用仍不清楚。
采用免疫组织化学和多色免疫荧光技术分析c-Myc表达和免疫细胞浸润。使用western blotting分析c-Myc和β-catenin表达。采用流式细胞术定量免疫抑制配体——包括程序性死亡配体1(PD-L1)、CD47、CD155和人类白细胞抗原-E(HLA-E)——的表达,并表征T细胞和巨噬细胞的功能。使用酶联免疫吸附试验评估细胞因子水平。
c-Myc在TIL(肿瘤浸润淋巴细胞)高浸润(TIL high)肿瘤中的表达高于TIL low肿瘤(n = 24),且与CD163 + 巨噬细胞浸润呈正相关(p = 0.0180)。免疫抑制配体在SCLC细胞上普遍表达。10058-F4——一种c-Myc抑制剂——显著下调PD-L1、CD47和CD155的表达,并上调HLA-E表达。在共培养系统中,抑制SCLC细胞中的c-Myc显著上调Jurkat细胞中干扰素-γ的产生,抑制巨噬细胞吞噬作用,并降低上清液中的细胞因子浓度。进一步的机制研究揭示,c-Myc抑制调节Notch信号通路,并降低E-cadherin、血管内皮(VE)-cadherin和β-catenin的表达。一种β-catenin激动剂改善了10058-F4对SCLC细胞中免疫抑制配体的调节作用。
Small cell lung carcinoma (SCLC) is a highly aggressive, rapidly proliferating malignancy largely corresponding to immune-cold tumor type. The role of the key oncogene c-Myc in regulating the complex immune microenvironment of SCLC remains unknown.
Immunohistochemistry and multiplex immunofluorescence techniques were used to analyze c-Myc expression and immune cell infiltration. c-Myc and β-catenin expression were analyzed using western blotting. Flow cytometry was used to quantify the expression of immunosuppressive ligands-including programmed death ligand 1 (PD-L1), CD47, CD155, and human leukocyte antigen-E (HLA-E)-and characterize the function of T cells and macrophages. Cytokine levels were evaluated using enzyme-linked immunosorbent assays.
c-Myc expression in high tumor-infiltrating lymphocyte infiltration (TIL high ) tumor exceeded that in TIL low tumors ( n = 24) and was positively correlated with CD163 + macrophage infiltration ( p = 0.0180). Immunosuppressive ligands were universally expressed on SCLC cells. 10058-F4-a c-Myc inhibitor-substantially downregulated the expression of PD-L1, CD47, and CD155 and upregulated HLA-E expression. In the coculture system, the inhibition of c-Myc in SCLC cells significantly upregulated interferon-gamma production in Jurkat cells, inhibited macrophage phagocytosis, and decreased cytokine concentrations in the supernatant. Further mechanistic studies revealed that c-Myc inhibition modulated the Notch signaling pathway and reduced the expression of E-cadherin, vascular endothelial (VE)-cadherin, and β-catenin. A β-catenin agonist improved the regulatory effect of 10058-F4 on the immunosuppressive ligands in SCLC cells.
c-Myc expression in SCLC is associated with immune infiltration and may regulate the expression of immune-related ligands on SCLC cells via WNT/β-catenin signaling.
MEMBER ACCOUNT
登录成功会直接打开下一页。